Study finds vaccine extends recurrent gliobastoma survival rates by 2 to 3 times

Jun 03, 2011

In data presented at The American Society of Clinical Oncology (ASCO) Annual Meeting, cancer researchers found that the brain tumor vaccine HSPPC-96 for treating recurrent gliobastoma has a favorable safety profile and extends survival by 2 to 3 times more than the current median survival rate. Patients in the study, conducted at University Hospitals Case Medical Center, University of California, San Francisco, and Columbia University, were found to have a median survival of 11 months compared to current 3 to 5 month survival.

"The findings are very favorable for patients with this deadly form of brain cancer," said Andrew Sloan MD, one of the authors of the study presented at ASCO and Director of the Brain Tumor and Neuro-Oncology Center at University Hospitals Case Medical Center. "The vaccine is one of the few immune therapies designed specifically for patients who are not newly diagnosed, and these encouraging results make this a promising therapy for a more extensive Phase 3 trial."

HSPPC-96 isolates the heat shock protein, which is part of the immune system. The protein from the patient's tumor is then reinjected into the skin with an adjuvant, or an agent added to a drug to increase its effect.

The vaccine was developed by Andrew Parsa MD PhD, principal investigator of the Brain Tumor Research Center at the University of California, San Francisco. He is collaborating with the Lexington, Massachusetts biotech company called Agenus. Columbia University also is part of the ongoing Phase 2 study designed to evaluate overall survival and immunologic response with HSPPC-96 in patients with first or subsequent recurrence of gliobastoma.

All patients underwent surgery prior to vaccine therapy. However, since the vaccine is made from the patient's own tumor, the surgery had to be performed at 1 of the participating sites. The vaccine therapy begins within 5 weeks after surgery and consists of 4 weekly injections, followed by biweekly injections for up to 52 weeks.

"The vaccine is made from a patient's own cells, so it takes into account what is unique about the patient's particular tumor—it's the ultimate in 'personalized medicine'," said Dr Sloan who also is the Peter D Cristal Chair in Neurosurgery and an Associate Professor of Neurological Surgery at Case Western Reserve University School of Medicine.

Source: News Release
University Hospitals Case Medical Center
June 3, 2011